As you suggested it seemed at least a possibility that GLPG may get FDA to reconsider the 200mg dose perhaps even before the start of the Phase 3 with more (EU) patients exposed or perhaps a 150mg daily dose. This from the F-1
GLPG—If Filgotinib is ultimately approved with a dose limitation for males, this will be a major impediment commercially, IMO, even if the rationale for the dose limitation is scientifically valid.